Cargando…
Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued comb...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/ https://www.ncbi.nlm.nih.gov/pubmed/32914066 http://dx.doi.org/10.1002/iju5.12173 |
_version_ | 1783578476308070400 |
---|---|
author | Maegawa, Yoko Kato, Taigo Fukuhara, Shinichiro Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Nonomura, Norio Fujita, Kazutoshi |
author_facet | Maegawa, Yoko Kato, Taigo Fukuhara, Shinichiro Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Nonomura, Norio Fujita, Kazutoshi |
author_sort | Maegawa, Yoko |
collection | PubMed |
description | INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune‐related adverse events is largely unknown. CASE PRESENTATION: We report the case of 74‐year‐old man who received combination therapy with anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune‐related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti‐programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. CONCLUSION: The readministration of anti‐programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy. |
format | Online Article Text |
id | pubmed-7469840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74698402020-09-09 Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma Maegawa, Yoko Kato, Taigo Fukuhara, Shinichiro Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Nonomura, Norio Fujita, Kazutoshi IJU Case Rep Case Report INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune‐related adverse events is largely unknown. CASE PRESENTATION: We report the case of 74‐year‐old man who received combination therapy with anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune‐related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti‐programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. CONCLUSION: The readministration of anti‐programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy. John Wiley and Sons Inc. 2020-06-25 /pmc/articles/PMC7469840/ /pubmed/32914066 http://dx.doi.org/10.1002/iju5.12173 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Maegawa, Yoko Kato, Taigo Fukuhara, Shinichiro Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Nonomura, Norio Fujita, Kazutoshi Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title | Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title_full | Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title_fullStr | Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title_full_unstemmed | Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title_short | Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
title_sort | resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/ https://www.ncbi.nlm.nih.gov/pubmed/32914066 http://dx.doi.org/10.1002/iju5.12173 |
work_keys_str_mv | AT maegawayoko resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT katotaigo resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT fukuharashinichiro resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT kiuchihiroshi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT imamuraryoichi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT uemuramotohide resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT nonomuranorio resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT fujitakazutoshi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma |